Seth joined Wilson Sonsini Goodrich & Rosati in September 2006 after serving for six years at the Federal Trade Commission. During his tenure at the FTC, Seth obtained unique experience and insights into the commission's antitrust activities and enforcement practices, having served at all levels of the commission.

From 2004 to 2006 he served as antitrust advisor to Commissioner (now Chairman) Jon Leibowitz, advising him on enforcement issues relating to both anticompetitive conduct and mergers affecting various industries including health care, medical devices, media, and oil and gas. In addition, he provided substantial support to Commissioner Leibowitz's policy initiatives involving pharmaceutical issues and telecommunications.

Seth also served in the Bureau of Competition's front office as an Assistant to the Bureau Director. In that position, he reviewed recommendations from the bureau staff on both merger and non-merger matters, with a particular emphasis on pharmaceutical matters.

During his first three years at the FTC, Seth was a staff attorney in the bureau's Health Care Division. He was a lead attorney in FTC v. Schering-Plough, and was involved in many of the commission's investigations involving pharmaceutical patent settlements and Orange Book listings. While in the Health Care Division, he also conducted several merger investigations, and served as the division's liaison to the Food and Drug Administration.

Seth is active in the American Bar Association's Antitrust Section, serving since 2007 as the chair of the Health Care and Pharmaceuticals Committee. He is the lead editor of the first-ever treatise on pharmaceutical antitrust—the Pharmaceutical Industry Antitrust Handbook, published by the ABA in 2009.

Prior to joining the FTC, Seth was in private practice at Paul Hastings in Washington, D.C. He also is part-owner/treasurer of the Potomac Nationals, the Class-A affiliate of the Washington Nationals.

Seth C. Silber continued

• J.D., George Washington University Law School, 1997
  Cum Laude
• M.A., Johns Hopkins School of Advanced International Studies (SAIS), 1993
• B.A., Emory University, 1991
  Cum Laude

• Chair, American Bar Association Antitrust Section's Health Care and Pharmaceuticals Committee

• Lead Editor, Pharmaceutical Antitrust Industry Handbook, ABA Section of Antitrust Law, July 2009
• Co-author with Susan Creighton, "EC's Preliminary Pharmaceutical Sector Report: An Aggressive Review of Industry Conduct," Global Competition Policy, February 2009
• Co-author with Matthew Bye, "Is That Everything? Antitrust Filing Obligations for Pharmaceutical Settlement Agreements," Antitrust Compliance Bulletin, ABA Section of Antitrust Law, Vol. 2, No. 1, March 2008
• "Cephalon: FTC's Challenge to Patent Settlements," Competition Law360, February 19, 2008
• "Settlements with Payments to Generics Increase: FTC," Competition Law360, March 28, 2007
• "FTC Review of Generic Drug Mergers," Journal of Generic Medicines, February 13, 2007

Seth speaks frequently on antitrust issues. His prior speaking engagements have focused on FTC enforcement in the pharmaceutical area, authorized generics, pharmacy benefits managers (PBMs), and merger enforcement. Some recent engagements include:

• "Setting the Framework: Antitrust Review of Reverse-Payment Patent Settlements," Bates White Healthcare Law and Economics Workshop, October 29, 2009
• "Pharmaceutical Antitrust Initiatives and Developments in the U.S. and Abroad," American Conference Institute, July 29, 2009
• "Mitigating Antitrust Concerns When Settling Paragraph IV Disputes," American Conference Institute's Conference on Paragraph IV Litigation, April 29, 2009
• Conference Co-chair, Fourth Annual In-House Counsel Forum on Pharmaceutical Antitrust, May 20-21, 2008
• "Merger Review and the Pharmaceutical Industry," Law Seminars International Conference on Pharmaceutical Antitrust, April 24, 2008
• "Pharmaceutical Antitrust Issues in the United States," European Pharmaceutical Law Forum, October 2007
• "Antitrust Issues Relating to Generic Competition," ABA/AHLA Conference on Antitrust in Health Care, September 18, 2007
• Conference Co-chair (and Panelist on Authorized Generics), Third Annual In-House Counsel Forum on Pharmaceutical Antitrust, May 15-16, 2007
• "Biotech Mergers: FTC Review and Guidance," Biotechnology 2007 Conference, January 29, 2007
• "Authorized Generics: Their Role in the Marketplace, and the FTC Study," ABA Health Care Committee Panel, September 2006

Seth C. Silber continued

• Keynote Address, "FTC Initiatives to Promote Pharmaceutical Competition," American Conference Institute's Conference on Maximizing Pharmaceutical Patent Life Cycles, June 14, 2006
• Panel Participant on Authorized Generics, Second Annual In-House Counsel's Forum on Pharmaceutical Antitrust, April 24, 2006
• Presentation on Authorized Generics, In-House Counsel's Forum on Pharmaceutical Antitrust, May 24, 2005
• "FTC's Actions Affecting Generic Drug Markets," Generic Pharmaceutical Association, 2005 Legal Symposium, May 18, 2005
• "Update on FTC's Views and Findings on the PBM Market," Second Annual Forum on Minimizing Legal Risk in Pharmaceutical Benefit Management, April 18, 2005
• "FTC Enforcement Priorities," 4th Annual Generic Drug Forum, November 17, 2004
• "FTC's PBM Activities," Forum on Minimizing Legal Risk in Pharmaceutical Benefit Management, March 22, 2003
• Presentations on Investigational Planning, Interviewing Techniques, and Oral Argument, Federal Trade Commission International Technical Assistance Program, "Investigative Techniques Workshop: Unilateral Refusals to Deal and Essential Facilities", Ljubljana, Slovenia, April 2003

• Bar of the District of Columbia